Korro Bio (NASDAQ: KRRO) director receives 14,677 stock options grant

Rhea-AI Filing Summary

Korro Bio director Timothy R. Pearson reported receiving a grant of stock options under the company’s equity plan. The award covers 14,677 options for Common Stock at an exercise price of $10.59 per share, with no cash paid for the grant itself.

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a non-employee director through that date. Following this grant, Pearson holds 14,677 stock options directly, which expire on June 9, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PEARSON TIMOTHY R

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,677	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,677 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 14,677 options Exercise price: $10.59 per share Expiration date: June 9, 2036 +1 more

4 metrics

Stock options granted 14,677 options Grant to director Timothy R. Pearson

Exercise price $10.59 per share Stock option strike price

Expiration date June 9, 2036 Option term end date

Underlying shares 14,677 shares Common Stock Shares covered by options

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 10.5900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares subject to the option vest in full on the earlier"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders"

non-employee director financial

"subject to continued service as a non-employee director"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PEARSON TIMOTHY R

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.59	06/10/2026		A		14,677		(1)	06/09/2036	Common Stock	14,677	$0	14,677	D

Explanation of Responses:

1. The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.

	/s/ Jeffrey Cerio, attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Korro Bio (KRRO) report for Timothy R. Pearson?

Korro Bio reported that director Timothy R. Pearson received a grant of 14,677 stock options. These options give him the right to buy Common Stock at $10.59 per share as part of his director compensation, rather than reflecting an open-market purchase or sale.

How many Korro Bio (KRRO) stock options were granted to Timothy R. Pearson?

Timothy R. Pearson was granted 14,677 stock options linked to Korro Bio Common Stock. Each option allows him to acquire one share at a fixed exercise price of $10.59, subject to vesting conditions tied to his continued service as a non-employee director.

What is the exercise price and expiration date of Timothy R. Pearson’s Korro Bio options?

The granted stock options carry an exercise price of $10.59 per share and expire on June 9, 2036. This long-dated expiration gives Pearson a multi-year window to exercise the options once they vest, assuming he remains eligible to do so.

When do Timothy R. Pearson’s Korro Bio (KRRO) stock options vest?

The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders. Vesting is conditional on Pearson’s continued service as a non-employee director through the applicable vesting date, aligning rewards with board tenure.

Was Timothy R. Pearson’s Korro Bio Form 4 transaction a market purchase or sale?

No, the Form 4 reflects a compensation-related grant, not a market trade. Pearson received 14,677 stock options as a grant with a $10.59 exercise price, and no shares were bought or sold in the open market in this reported transaction.

How many Korro Bio (KRRO) stock options does Timothy R. Pearson hold after this grant?

After the reported grant, Timothy R. Pearson holds 14,677 stock options directly. These options relate to Korro Bio Common Stock and represent his entire position reported in this filing, since no additional derivative holdings appear in the derivative position summary.